Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
2.5 ^USD	+2.04%		-10.71%	+47.06%

Apr. 23	Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	MT
Mar. 21	Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	CI

Heron Therapeutics, Inc. Reiterates Net Product Sales Guidance for the Full Year 2023

August 14, 2023 at 04:05 pm EDT

Heron Therapeutics, Inc. reiterated net product sales guidance for the full year 2023. The company is reiterating full-year 2023 net product sales guidance for the oncology care franchise of $99 million to $103 million.

Latest news about Heron Therapeutics, Inc.

Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	Apr. 23	MT
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	Mar. 21	CI
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	Mar. 13	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Mar. 13	MT
Heron Therapeutics Shares Soar After Q4 Results Beat	Mar. 13	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating	Mar. 13	MT
Transcript : Heron Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M	Mar. 12	MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	Mar. 12	CI
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef	Jan. 24	DJ
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	Jan. 24	MT
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	Jan. 23	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding	Jan. 08	MT
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket	Jan. 08	MT
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF	Jan. 07	CI
Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023	Dec. 21	CI
Heron Therapeutics Insider Bought Shares Worth $137,970, According to a Recent SEC Filing	Nov. 17	MT
Needham Trims Price Target on Heron Therapeutics to $4 From $5, Keeps Buy Rating	Nov. 15	MT
Transcript : Heron Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q3 Revenue $31.4M, vs. Street Est of $31.8M	Nov. 14	MT
Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024	Nov. 14	CI
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : Heron Therapeutics, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14

Chart Heron Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Heron Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.45 USD

Average target price

6.75 USD

Spread / Average Target

+175.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HERON THERAPEUTICS, INC.	+47.06%	368M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research